Trial Details
Not RecruitingBasic Information
| Clinical ID | c3340 |
|---|---|
| Identifier | ACTRN12607000617460 |
| Trial Title | Phase IIa examination of the effect of oral dosing of NV-52 on surrogate markers of inflammatory bowel disease (IBD) in patients with stable disease but with a consistent abnormality in one or more surrogate marker. |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Crohn's disease and Ulcerative Colitis; Crohn's disease and Ulcerative Colitis;Oral and Gastrointestinal - Crohn's disease;Oral and Gastrointestinal - Inflammatory bowel disease |
| Interventions | NV-52 will be administered orally, once daily at a dose of 50mg/day for 4 weeks. |
Participant Information
| Sponsor | Novogen Research Pty Ltd |
|---|---|
| City | - |
| Country/Region | Australia |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |